LABORATOIRES EUROMEDIS (ALEMG.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALEMG - FR0000075343 - Common Stock
4.13 EUR
+0.18 (+4.56%)
ALEMG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 63 industry peers in the Health Care Equipment & Supplies industry. The financial health of ALEMG is average, but there are quite some concerns on its profitability. ALEMG is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- ALEMG had negative earnings in the past year.
- In multiple years ALEMG reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: ALEMG reported negative operating cash flow in multiple years.
1.2 Ratios
- ALEMG has a worse Return On Assets (-13.77%) than 73.02% of its industry peers.
- Looking at the Return On Equity, with a value of -33.03%, ALEMG is doing worse than 71.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.77% | ||
| ROE | -33.03% | ||
| ROIC | N/A |
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ALEMG has a Gross Margin of 26.77%. This is amonst the worse of the industry: ALEMG underperforms 87.30% of its industry peers.
- ALEMG's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for ALEMG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
- ALEMG has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for ALEMG has been reduced compared to 5 years ago.
- Compared to 1 year ago, ALEMG has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 1.84 indicates that ALEMG is not a great score, but indicates only limited risk for bankruptcy at the moment.
- ALEMG has a Altman-Z score of 1.84. This is in the lower half of the industry: ALEMG underperforms 61.90% of its industry peers.
- ALEMG has a Debt/Equity ratio of 0.52. This is a neutral value indicating ALEMG is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.52, ALEMG is in line with its industry, outperforming 44.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.84 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 3.07 indicates that ALEMG has no problem at all paying its short term obligations.
- ALEMG has a Current ratio of 3.07. This is amongst the best in the industry. ALEMG outperforms 84.13% of its industry peers.
- ALEMG has a Quick Ratio of 2.25. This indicates that ALEMG is financially healthy and has no problem in meeting its short term obligations.
- ALEMG's Quick ratio of 2.25 is amongst the best of the industry. ALEMG outperforms 84.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.07 | ||
| Quick Ratio | 2.25 |
3. Growth
3.1 Past
- ALEMG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -144.11%.
- ALEMG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.59%.
- ALEMG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -14.02% yearly.
EPS 1Y (TTM)-144.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.64%
Revenue 1Y (TTM)-26.59%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%11.95%
3.2 Future
- Based on estimates for the next years, ALEMG will show a small growth in Earnings Per Share. The EPS will grow by 7.07% on average per year.
- Based on estimates for the next years, ALEMG will show a very negative growth in Revenue. The Revenue will decrease by -18.80% on average per year.
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- ALEMG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- The Price/Forward Earnings ratio is 8.74, which indicates a very decent valuation of ALEMG.
- Based on the Price/Forward Earnings ratio, ALEMG is valued cheaper than 95.24% of the companies in the same industry.
- ALEMG is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.72, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.74 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ALEMG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.07%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for ALEMG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
LABORATOIRES EUROMEDIS / ALEMG.PA FAQ
What is the ChartMill fundamental rating of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ALEMG.PA.
Can you provide the valuation status for LABORATOIRES EUROMEDIS?
ChartMill assigns a valuation rating of 3 / 10 to LABORATOIRES EUROMEDIS (ALEMG.PA). This can be considered as Overvalued.
What is the profitability of ALEMG stock?
LABORATOIRES EUROMEDIS (ALEMG.PA) has a profitability rating of 1 / 10.
How financially healthy is LABORATOIRES EUROMEDIS?
The financial health rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 5 / 10.
How sustainable is the dividend of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?
The dividend rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 0 / 10 and the dividend payout ratio is 0%.